Andersen H, Botta G, Galasse R, Hill J F
Postgrad Med J. 1986;62 Suppl 1:146-9.
One hundred and ten mild and moderately hypertensive patients were treated with a fixed combination of captopril 50 mg and hydrochlorothiazide 25 mg (Capozide 50) once daily for 12 months. Eighty four patients were treated initially with Capozide 50 12 hourly for 3 months before receiving Capozide 50 o.d.; the other 26 patients received Capozide 50 as initial treatment immediately after the placebo run-in period. Blood pressures were measured 24 hours after ingestion of the drug. Capozide 50 once daily induced statistically significant reductions in supine blood pressure and these beneficial effects were sustained throughout the duration of the trial. In patients receiving Capozide 50 as initial therapy, a gradual hypotensive effect was seen. No clinically significant changes in biochemical or haematological variables were recorded although a small but statistically significant rise in uric acid was noted. This latter effect was attributed to the thiazide component of the combination. The efficacy and safety profile of this once-a-day compound makes it an ideal therapeutic agent for the management of mild and moderate hypertension.
110例轻度和中度高血压患者接受卡托普利50毫克和氢氯噻嗪25毫克的固定复方制剂（复方卡托普利50）治疗，每日1次，疗程12个月。84例患者在接受复方卡托普利50每日1次治疗前，先以复方卡托普利50每12小时1次治疗3个月；另外26例患者在安慰剂导入期后立即接受复方卡托普利50作为初始治疗。在服药24小时后测量血压。复方卡托普利50每日1次可使仰卧位血压出现具有统计学意义的下降，且这些有益作用在整个试验期间持续存在。在接受复方卡托普利50作为初始治疗的患者中，可见逐渐的降压效果。尽管尿酸有小幅但具有统计学意义的升高，但未记录到生化或血液学指标有临床显著变化。后一效应归因于该复方制剂中的噻嗪类成分。这种每日1次复方制剂的疗效和安全性使其成为治疗轻度和中度高血压的理想治疗药物。
